RecruitingNot Applicable

Cardiac RadiothErapy for VEntricular Tachycardia II

Belgium50 participantsStarted 2025-01-01

Plain-language summary

Steoreotactic therapy radioablation has become a standard of care option for patients with therapy-refractory ventricular tachycardia, yet long-term outcome is lacking. The objective of this study is to evaluate the long-term outcomes, both efficacy and safety, after STAR in patients with therapy-refractory ventricular tachycardia.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Eligible for STAR for therapy-refractory VT based on a multidisciplinary discussion * Ability to give a written informed consent and willingness to return for follow-up Exclusion Criteria: * Contra-indications for STAR, including pregnancy or breastfeeding, previous radiotherapy with cardiac involvement, life-expectancy \< 6 months in the absence of VT * Any condition that is deemed a contraindication in the judgment of the investigators

What they're measuring

Change in VT burden

Timeframe: 48 months

Trial details

NCT IDNCT06744530

SponsorUniversitaire Ziekenhuizen KU Leuven

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2033-12

Contact for this trial

Bert Vandenberk, MD PhD

+3216338686 bert.vandenberk@uzleuven.be

View on ClinicalTrials.gov More Ventricular Tachycardia (VT) trials